KR102604900B1 - Irak4 억제제로서 유용한 티에노피리딘 및 벤조티오펜 - Google Patents

Irak4 억제제로서 유용한 티에노피리딘 및 벤조티오펜 Download PDF

Info

Publication number
KR102604900B1
KR102604900B1 KR1020197036216A KR20197036216A KR102604900B1 KR 102604900 B1 KR102604900 B1 KR 102604900B1 KR 1020197036216 A KR1020197036216 A KR 1020197036216A KR 20197036216 A KR20197036216 A KR 20197036216A KR 102604900 B1 KR102604900 B1 KR 102604900B1
Authority
KR
South Korea
Prior art keywords
methoxy
pyridine
carboxamide
oxopyrrolidin
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197036216A
Other languages
English (en)
Korean (ko)
Other versions
KR20200004871A (ko
Inventor
살림 아마드
링 리
리데트 에이. 네가쉬
존 하인스
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20200004871A publication Critical patent/KR20200004871A/ko
Application granted granted Critical
Publication of KR102604900B1 publication Critical patent/KR102604900B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020197036216A 2017-05-11 2018-05-10 Irak4 억제제로서 유용한 티에노피리딘 및 벤조티오펜 Active KR102604900B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762504956P 2017-05-11 2017-05-11
US62/504,956 2017-05-11
PCT/US2018/031945 WO2018209012A1 (en) 2017-05-11 2018-05-10 Thienopyridines and benzothiophenes useful as irak4 inhibitors

Publications (2)

Publication Number Publication Date
KR20200004871A KR20200004871A (ko) 2020-01-14
KR102604900B1 true KR102604900B1 (ko) 2023-11-21

Family

ID=62245511

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197036216A Active KR102604900B1 (ko) 2017-05-11 2018-05-10 Irak4 억제제로서 유용한 티에노피리딘 및 벤조티오펜

Country Status (29)

Country Link
US (1) US10829496B2 (https=)
EP (1) EP3621960B1 (https=)
JP (1) JP7154229B2 (https=)
KR (1) KR102604900B1 (https=)
CN (1) CN110612298B (https=)
AR (1) AR111689A1 (https=)
AU (1) AU2018265130B2 (https=)
BR (1) BR112019023290A2 (https=)
CA (1) CA3062602A1 (https=)
CL (1) CL2019003198A1 (https=)
CO (1) CO2019012494A2 (https=)
CY (1) CY1124552T1 (https=)
DK (1) DK3621960T3 (https=)
EA (1) EA039189B1 (https=)
ES (1) ES2889926T3 (https=)
HR (1) HRP20211583T1 (https=)
HU (1) HUE056493T2 (https=)
IL (1) IL270494B (https=)
LT (1) LT3621960T (https=)
MX (1) MX2019012929A (https=)
MY (1) MY200228A (https=)
PE (1) PE20191817A1 (https=)
PL (1) PL3621960T3 (https=)
PT (1) PT3621960T (https=)
RS (1) RS62430B1 (https=)
SI (1) SI3621960T1 (https=)
SM (1) SMT202100568T1 (https=)
TW (1) TW201900640A (https=)
WO (1) WO2018209012A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
MX2020003190A (es) 2017-09-22 2020-11-11 Kymera Therapeutics Inc Degradadores de proteinas y usos de los mismos.
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
JP7623943B2 (ja) 2018-11-30 2025-01-29 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
BR112021026517A2 (pt) 2019-06-28 2022-05-10 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN114127075B (zh) 2019-07-18 2024-05-14 百时美施贵宝公司 可用作IRAK4抑制剂的吡唑并[3,4-d]吡咯并[1,2-b]哒嗪基化合物
EP3999508B1 (en) 2019-07-18 2023-08-30 Bristol-Myers Squibb Company Tricyclic heteroaryl compounds useful as irak4 inhibitors
JP7573596B2 (ja) * 2019-07-23 2024-10-25 ブリストル－マイヤーズ スクイブ カンパニー Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
WO2021026181A1 (en) 2019-08-06 2021-02-11 Bristol-Myers Squibb Company Bicyclic heterocyclic compounds useful as irak4 inhibitors
ES3059914T3 (en) 2019-08-13 2026-03-24 Bristol Myers Squibb Co Bicyclic heteroaryl compounds useful as irak4 inhibitors
US12551564B2 (en) 2019-12-10 2026-02-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021127190A1 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021158495A1 (en) 2020-02-03 2021-08-12 Bristol-Myers Squibb Company Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors
CN111285844B (zh) * 2020-02-24 2022-08-12 河南师范大学 具有生物活性的苯并噻吩取代酰胺类化合物及其合成方法和应用
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
PH12023500015A1 (en) 2020-12-30 2024-03-11 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2022174268A1 (en) 2021-02-15 2022-08-18 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
US12187744B2 (en) 2021-10-29 2025-01-07 Kymera Therapeutics, Inc. IRAK4 degraders and synthesis thereof
EP4472967A4 (en) 2022-01-31 2026-04-15 Kymera Therapeutics Inc Iraqi Degradation Agents and Their Uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013106612A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
WO2014074657A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8627698D0 (en) * 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
US6825190B2 (en) 2001-06-15 2004-11-30 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
AU2003244098A1 (en) 2002-06-28 2004-01-19 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxa mide derivative
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
CA2531401A1 (en) 2003-07-10 2005-01-27 Neurogen Corporation Substituted heterocyclic diarylamine analogues
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
CN101171052A (zh) 2005-03-09 2008-04-30 先灵公司 抑制ksp驱动蛋白活性的化合物
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
JP2009526761A (ja) 2006-01-30 2009-07-23 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環式チオフェン化合物および使用の方法
KR20100020454A (ko) 2007-06-08 2010-02-22 바이엘 크롭사이언스 소시에떼아노님 살진균제 헤테로사이클릴-피리미디닐-아미노 유도체
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
JP5254693B2 (ja) 2008-07-30 2013-08-07 三菱重工業株式会社 Ｎｉ基合金用溶接材料
JPWO2010058846A1 (ja) 2008-11-21 2012-04-19 アステラス製薬株式会社 ４，６−ジアミノニコチンアミド化合物
WO2010061971A1 (ja) 2008-11-28 2010-06-03 興和株式会社 ピリジン－３－カルボキシアミド誘導体
JP5775070B2 (ja) 2009-05-22 2015-09-09 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
EP2440204B1 (en) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
IN2012DN02493A (https=) 2009-09-03 2015-08-28 Allergan Inc
EP2493863B1 (en) 2009-10-30 2015-02-25 Janssen Pharmaceutica NV Phenoxy-substituted pyrimidines as opioid receptor modulators
KR20120130104A (ko) 2010-02-01 2012-11-28 닛뽕 케미파 가부시키가이샤 Ｇｐｒ119 작동약
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
CN103619854A (zh) 2011-04-29 2014-03-05 西奈山伊坎医学院 激酶抑制剂
WO2013106614A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
CN104254533B (zh) 2012-01-13 2017-09-08 百时美施贵宝公司 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
KR20150079963A (ko) 2012-11-08 2015-07-08 브리스톨-마이어스 스큅 컴퍼니 키나제 조절제로서 유용한 헤테로아릴 치환된 피리딜 화합물
US9315494B2 (en) 2012-11-08 2016-04-19 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
MA39838B1 (fr) 2014-04-04 2019-05-31 Pfizer Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
EP3268003B1 (en) * 2015-03-12 2020-07-29 Merck Sharp & Dohme Corp. Thienopyrazine inhibitors of irak4 activity
US10155765B2 (en) * 2015-03-12 2018-12-18 Merck Sharp & Dohme Corp. Carboxamide inhibitors of IRAK4 activity
ES2822956T3 (es) 2015-06-24 2021-05-05 Bristol Myers Squibb Co Compuestos de aminopiridina sustituidos con heteroarilo
TW201718571A (zh) 2015-06-24 2017-06-01 必治妥美雅史谷比公司 經雜芳基取代之胺基吡啶化合物
ES2865199T3 (es) * 2015-08-27 2021-10-15 Pfizer Compuestos de heteroarilo o arilo condensados bicíclicos como moduladores de IRAK4

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013106612A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
WO2014074657A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators

Also Published As

Publication number Publication date
HRP20211583T1 (hr) 2022-01-07
BR112019023290A2 (pt) 2020-06-16
WO2018209012A1 (en) 2018-11-15
PT3621960T (pt) 2021-09-16
US10829496B2 (en) 2020-11-10
EA201992674A1 (ru) 2020-04-06
MY200228A (en) 2023-12-15
SMT202100568T1 (it) 2021-11-12
AU2018265130A1 (en) 2020-01-02
HUE056493T2 (hu) 2022-02-28
EA039189B1 (ru) 2021-12-15
CA3062602A1 (en) 2018-11-15
EP3621960B1 (en) 2021-08-04
ES2889926T3 (es) 2022-01-14
KR20200004871A (ko) 2020-01-14
CL2019003198A1 (es) 2020-03-20
CN110612298B (zh) 2023-05-05
CO2019012494A2 (es) 2020-01-17
EP3621960A1 (en) 2020-03-18
CN110612298A (zh) 2019-12-24
MX2019012929A (es) 2020-01-14
IL270494B (en) 2022-04-01
AR111689A1 (es) 2019-08-07
PL3621960T3 (pl) 2021-11-08
AU2018265130B2 (en) 2022-03-24
CY1124552T1 (el) 2022-07-22
JP2020519596A (ja) 2020-07-02
RS62430B1 (sr) 2021-11-30
TW201900640A (zh) 2019-01-01
JP7154229B2 (ja) 2022-10-17
US20200062777A1 (en) 2020-02-27
DK3621960T3 (da) 2021-09-27
SI3621960T1 (sl) 2021-11-30
PE20191817A1 (es) 2019-12-27
LT3621960T (lt) 2021-10-11

Similar Documents

Publication Publication Date Title
KR102604900B1 (ko) Irak4 억제제로서 유용한 티에노피리딘 및 벤조티오펜
KR102688509B1 (ko) [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물
JP6843775B2 (ja) ヘテロアリール置換のアミノピリジン化合物
KR101716011B1 (ko) Btk 활성의 억제제인 알킬화된 피페라진 화합물
US10202390B2 (en) Heteroaryl substituted aminopyridine compounds
CA3083374A1 (en) Heterocyclic compounds as prmt5 inhibitors
KR102679517B1 (ko) Tnf 알파의 조정제로서 유용한 시클릭 화합물
KR20220079587A (ko) 치환된 카르바졸 화합물
KR20220006571A (ko) 치환된 벤즈이미다졸론 화합물
US12304914B2 (en) Pyrazolo[3,4-d]pyrrolo[1,2-b]pyridazinyl compounds useful as IRAK4 inhibitors
JP7573596B2 (ja) Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
KR102956430B1 (ko) IRAK4 억제제로서 유용한 피라졸로[3,4-d]피롤로[1,2-b]피리다지닐 화합물
KR20220136395A (ko) Irak4 억제제로서 유용한 트리시클릭 헤테로아릴 화합물
KR20220035446A (ko) Irak4 억제제로서 유용한 트리시클릭 헤테로아릴 화합물

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191206

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210510

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230328

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230907

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231117

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231117

End annual number: 3

Start annual number: 1

PG1601 Publication of registration